Total Payments
$4,421
2024 Payments
$1,627
Companies
34
Transactions
170
Medicare Patients
4,207
Medicare Billing
$635,177
Payment Breakdown by Category
Food & Beverage$3,712 (84.0%)
Travel$687.44 (15.6%)
Education$21.70 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,712 | 165 | 84.0% |
| Travel and Lodging | $687.44 | 4 | 15.6% |
| Education | $21.70 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CVRx, Inc. | $794.47 | 5 | $0 (2024) |
| Novo Nordisk Inc | $491.75 | 23 | $0 (2024) |
| Amgen Inc. | $430.09 | 28 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $392.87 | 15 | $0 (2024) |
| Abbott Laboratories | $363.36 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $249.12 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $227.08 | 6 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $210.51 | 13 | $0 (2024) |
| Lilly USA, LLC | $148.61 | 10 | $0 (2024) |
| PFIZER INC. | $122.90 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,627 | 41 | CVRx, Inc. ($794.47) |
| 2023 | $710.02 | 36 | PFIZER INC. ($106.47) |
| 2022 | $680.71 | 38 | Amgen Inc. ($166.83) |
| 2021 | $448.10 | 26 | Boehringer Ingelheim Pharmaceuticals, Inc. ($80.07) |
| 2020 | $196.80 | 13 | Novo Nordisk Inc ($56.69) |
| 2019 | $46.94 | 3 | Novo Nordisk Inc ($46.94) |
| 2018 | $354.45 | 7 | Novo Nordisk Inc ($178.92) |
| 2017 | $356.64 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($107.38) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $149.75 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $217.74 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/13/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $107.03 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Endocrinology | ||||||
| 11/02/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Cardio-renal | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: Gastroenterology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $299.95 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Cardio-renal | ||||||
| 09/24/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Insomnia | ||||||
| 09/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: PAIN | ||||||
| 08/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.30 | General |
| Category: NEUROLOGY | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: Gastroenterology | ||||||
| 06/13/2024 | Avvisto Therapeutics, LLC | CYCLOSET (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: ANTI-DIABETIC | ||||||
| 06/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: DIABETES | ||||||
| 05/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Diabetes | ||||||
| 05/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/14/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Psychology/Psychiatric | ||||||
| 04/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,179 | 2,902 | $382,911 | $156,958 |
| 2022 | 15 | 1,149 | 3,187 | $401,102 | $154,697 |
| 2021 | 10 | 980 | 3,316 | $345,383 | $170,846 |
| 2020 | 10 | 899 | 2,777 | $237,617 | $152,676 |
Total Patients
4,207
Total Services
12,182
Medicare Billing
$635,177
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 106 | 1,292 | $193,820 | $78,122 | 40.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 82 | 180 | $36,250 | $16,344 | 45.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 79 | 161 | $32,494 | $15,521 | 47.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 100 | 113 | $39,500 | $15,062 | 38.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 42 | $10,820 | $5,893 | 54.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 474 | 680 | $10,967 | $4,311 | 39.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 34 | 107 | $10,630 | $4,106 | 38.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 27 | 28 | $10,990 | $4,079 | 37.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 21 | 21 | $10,500 | $3,258 | 31.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 16 | $5,600 | $2,612 | 46.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 17 | $4,510 | $2,183 | 48.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 26 | 30 | $4,500 | $1,594 | 35.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 82 | 129 | $3,870 | $1,445 | 37.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 23 | 23 | $2,760 | $1,370 | 49.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 17 | $3,400 | $427.04 | 12.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 23 | 23 | $1,150 | $380.19 | 33.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 23 | 23 | $1,150 | $251.16 | 21.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 79 | 1,479 | $222,340 | $80,935 | 36.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 77 | 207 | $41,200 | $16,284 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 65 | 162 | $32,572 | $16,120 | 49.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 76 | 79 | $27,475 | $12,039 | 43.8% |
| 99358 | Extended patient service without direct patient contact, first hour | Office | 2022 | 61 | 91 | $18,200 | $7,637 | 42.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 525 | 779 | $15,959 | $5,051 | 31.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 31 | $7,960 | $4,030 | 50.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 18 | 19 | $7,970 | $2,711 | 34.0% |
About Dr. Amyn Malik, MD
Dr. Amyn Malik, MD is a Cardiovascular Disease healthcare provider based in Grapevine, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/12/2009. The National Provider Identifier (NPI) number assigned to this provider is 1063651156.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amyn Malik, MD has received a total of $4,421 in payments from pharmaceutical and medical device companies, with $1,627 received in 2024. These payments were reported across 170 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($3,712).
As a Medicare-enrolled provider, Malik has provided services to 4,207 Medicare beneficiaries, totaling 12,182 services with total Medicare billing of $635,177. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Cardiovascular Disease
- Location Grapevine, TX
- Active Since 02/12/2009
- Last Updated 12/23/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1063651156
Products in Payments
- Barostim Neo System (Device) $794.47
- JARDIANCE (Drug) $414.58
- Saxenda (Drug) $311.46
- Otezla (Drug) $184.69
- Repatha (Biological) $171.57
- TactiCath Quartz CFA Catheter (Device) $163.26
- NURTEC ODT (Drug) $157.33
- ENTRESTO (Drug) $144.15
- FREESTYLE LIBRE 3 (Device) $131.09
- TRINTELLIX (Drug) $115.96
- CYCLOSET (Drug) $113.92
- XIFAXAN (Drug) $113.75
- VERQUVO (Drug) $107.86
- MULTAQ (Drug) $90.73
- Ozempic (Drug) $85.39
- LEQVIO (Drug) $82.93
- QUVIVIQ (Drug) $80.07
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $75.71
- BELSOMRA (Drug) $72.21
- Kerendia (Drug) $71.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Grapevine
John Osborne, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M
Dr. Vikas Jain, M.d, M.D
Cardiovascular Disease — Payments: $374,314
Cardiovascular Disease $374,314
Dr. Paul Bhella, M.d, M.D
Cardiovascular Disease — Payments: $294,139
Cardiovascular Disease $294,139
Raul Santos, Md, MD
Cardiovascular Disease — Payments: $10,376
Cardiovascular Disease $10,376
Dr. John Lawson, Md, MD
Cardiovascular Disease — Payments: $7,403
Cardiovascular Disease $7,403
Dr. Richard Feingold, D.o, D.O
Cardiovascular Disease — Payments: $3,790
Cardiovascular Disease $3,790